FonesLife offers the 7,000-plex SomaScan® Platform as Japan’s first SomaLogic™ Certified Site
TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that...
TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that...
Appointment brings more than 20 years of life sciences finance leadership experience to the CFO roleBURLINGTON, Mass., Dec. 19, 2022...
Mr. Lee brings almost 15 years of experience in strategy, M&A and partnering on more than $20 billion in transactions...
Funding from three leading healthcare investors, with Vivo Capital joining existing investors Nantahala Capital and Abingworth $10 million capital infusion...
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached...
-Reduced TGF-β2, but not TGF-β1 nor TGF-β3, is associated with improved OS. AGOURA HILLS, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE)...
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices...
BOTHELL, Wash., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces highly favorable safety and tolerability results...
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company...
NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company” or “Bioasis”), a multi-asset...
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology...
100% Survival Rate in Anthrax-infected Rabbits Treated with OmadacyclineTotal Revenue Recognition to Paratek of $38.1 MillionBOSTON, Dec. 19, 2022 (GLOBE...
TORONTO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) today announced...
Glofitamab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for B-cell non-Hodgkin’s lymphoma and other...
PRINCETON, N.J. and BENGALURU, India, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, today announced...
SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve...
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia...
Pfizer will now lead all development and commercialization activities in Mainland China, Hong Kong, Macau, and Singapore LianBio will receive...
ALACHUA, Fla. and TAMPA, Fla., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing...
REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated...